Karpec Diana, Rudys Romualdas, Leonaviciene Laima, Mackiewicz Zygmunt, Bradunaite Ruta, Kirdaite Gailute, Venalis Algirdas
State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania; The Clinic of Rheumatology, Traumatology Orthopaedics and Reconstructive Surgery, Institute of Clinical Medicine of the Faculty of Medicine of Vilnius University, Vilnius, Lithuania.
State Research Institute Centre for Innovative Medicine, Vilnius, Lithuania.
Adv Med Sci. 2018 Mar;63(1):152-159. doi: 10.1016/j.advms.2017.09.001. Epub 2017 Nov 6.
To define the efficacy and safety of narrowband ultraviolet A1 (UVA1) for the treatment of dermal fibrosis in bleomycin-induced mouse model of scleroderma.
42 DBA/2 strain mice were included in the study: healthy mice and mice with established scleroderma, treated with high or medium dose of UVA1. Non-treated groups served as control. The equipment emitting 365±5nm UVA1 radiation was used in the study. The average cumulative doses were 1200J/cm for high and 600J/cm for medium dose course. Histological analysis was performed for the evaluation of the dermal thickness and mast cells density. The expressions of p53 and Ki-67 proteins were assessed by immunohistochemical analyses.
Skin thickness of mice with scleroderma, treated with high and medium dose of UVA1, were lower (272.9±113.2μm and 394±125.9μm, respectively) in comparison to the dermal thickness of non-treated animals (599±55.7μm). The dermal mast cells count in mice with scleroderma was reduced after high and medium dose treatment to 11±1.7 and 13±2.2, respectively, as compared to that in non-treated mice (23±3.0). No significant upregulation of p53 nor Ki-67 proteins was observed in the skin of healthy mice and mice with scleroderma after high- and medium-dose of UVA1.
The results of this study indicate that 365nm UVA1 with the cumulative doses of 1200J/cm and 600J/cm is safe and effective for the dermal fibrosis treatment.
确定窄谱紫外线A1（UVA1）治疗博来霉素诱导的硬皮病小鼠模型中皮肤纤维化的疗效和安全性。
42只DBA/2品系小鼠纳入本研究：健康小鼠和已建立硬皮病模型的小鼠，分别接受高剂量或中剂量UVA1治疗。未治疗组作为对照。本研究使用发射365±5nm UVA1辐射的设备。高剂量疗程的平均累积剂量为1200J/cm²，中剂量疗程为600J/cm²。进行组织学分析以评估皮肤厚度和肥大细胞密度。通过免疫组织化学分析评估p53和Ki-67蛋白的表达。
与未治疗动物的皮肤厚度（599±55.7μm）相比，接受高剂量和中剂量UVA1治疗的硬皮病小鼠的皮肤厚度较低（分别为272.9±113.2μm和394±125.9μm）。与未治疗小鼠（23±3.0）相比，高剂量和中剂量治疗后硬皮病小鼠的真皮肥大细胞计数分别降至11±1.7和13±2.2。在健康小鼠和硬皮病小鼠的皮肤中，高剂量和中剂量UVA1治疗后未观察到p53和Ki-67蛋白的显著上调。
本研究结果表明，累积剂量为1200J/cm²和600J/cm²的365nm UVA1治疗皮肤纤维化安全有效。
